Att I - 60 day FRN

Attachment I: Federal Register/Vol.75,No.133/Tuesday,July13,2010/Notices
39947

Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Notices
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than August 6, 2010.
A. Federal Reserve Bank of Dallas (E.
Ann Worthy, Vice President) 2200
North Pearl Street, Dallas, Texas 75201–
2272:
1. Industry Bancshares, Inc., Industry
Texas; to acquire 100 percent of the
voting shares of The First National Bank
of Shiner, Shiner, Texas.
2. A.N.B. Holding Company, Ltd.,
Terrell, Texas; to acquire up to 32
percent of the voting shares of The ANB
Corporation, Terrell, Texas, and thereby
indirectly acquire voting shares of The
American National Bank of Texas,
Terrell, Texas; Lakeside Bancshares,
Inc., and Lakeside National Bank, both
of Rockwall, Texas.
Board of Governors of the Federal Reserve
System, July 8, 2010.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2010–16981 Filed 7–12–10; 8:45 am]
BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–10–0234]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed project or to obtain a copy of
data collection plans and instruments,
call the CDC Reports Clearance Officer
on 404–639–5960 or send comments to
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS D–74,
Atlanta, GA 30333 or send an e-mail to
[email protected].

combined across two years. This
increase will greatly improve the ability
to track providers’ practice patterns,
including their adoption and
meaningful use of health information
technology (HIT).
Congress may approve all, some or
none of the budget increase requested in
the President’s budget. If approved, this
notice would allow the proposed
request for a sample increase to move
forward to OMB for final review in
sufficient time to implement the sample
increase in the first quarter of 2011. This
notice also covers increases in sample
size that might result due to other
budget allocations.
NAMCS was conducted annually
from 1973 to 1981, again in 1985, and
resumed as an annual survey in 1989.
The purpose of NAMCS, a voluntary
survey, is to meet the needs and
demands for statistical information
about the provision of ambulatory
medical care services in the United
States. Ambulatory services are
rendered in a wide variety of settings,
including physicians’ offices and
hospital outpatient and emergency
departments. The NAMCS target
universe consists of all office visits
made by ambulatory patients to nonFederal office-based physicians
(excluding those in the specialties of
anesthesiology, radiology, and
pathology) who are engaged in direct
patient care. In 2006, physicians and
mid-level providers (i.e., nurse
practitioners, physician assistants, and
nurse midwives) practicing in
community health centers (CHCs) were
added to the NAMCS sample, and these
data will continue to be collected. To
complement NAMCS data, NCHS
initiated the National Hospital
Ambulatory Medical Care Survey
(NHAMCS, OMB No. 0920–0278) in
1992 to provide data concerning patient
visits to hospital outpatient and
emergency departments. NAMCS and
NHAMCS are the principal sources of
data on ambulatory care provided in the
United States. A three-year clearance is
requested.
There is no cost to the respondents
other than their time.

Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including the use of
automated collection techniques or
other forms of information technology.
Written comments should be received
within 60 days of this notice.
Proposed Project
National Ambulatory Medical Care
Survey (NAMCS), (OMB No. 0920–0234
exp. 7/31/2012)—Revision—National
Center for Health Statistics (NCHS),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Section 306 of the Public Health
Service (PHS) Act (42 U.S.C. 242k), as
amended, authorizes that the Secretary
of Health and Human Services (DHHS),
acting through NCHS, shall collect
statistics on the utilization of health
care provided by nonfederal officebased physicians in the United States.
On February 26, 2010, the Office of
Management and Budget (OMB)
approved data collection for three years.
This revision is to notify the public that
the President’s fiscal year 2011 budget
requests that Congress consider a budget
increase for this survey for 2011. If the
budget increase is approved by
Congress, expanded data collection will
begin in the first calendar quarter of
2011 or as soon thereafter as is possible.
An increased sample size of
approximately 6,800 physicians and
60,000 visit records (a doubling from
3,400 physicians and 30,000 visit
records sampled in 2010) is requested.
Currently the NAMCS produces
national and regional estimates. If the
full budget increase is approved by
Congress, the survey will be able to
produce the same estimates as it does
currently as well as data on a limited
number of states when data are

jlentini on DSKJ8SOYB1PROD with NOTICES

ESTIMATED ANNUALIZED BURDEN TABLE
Number of
respondents

Form
Induction Interview-Physicians/CHC Providers ...............................................
Patient Record Form .......................................................................................
EMR Mail Survey .............................................................................................
CHC Induction Interview-Facility ......................................................................

VerDate Mar<15>2010

16:44 Jul 12, 2010

Jkt 220001

PO 00000

Frm 00038

Fmt 4703

Sfmt 4703

Number of
responses per
respondent

7,112
2,797
10,302
208

E:\FR\FM\13JYN1.SGM

1
30
1
1

13JYN1

Avg. burden
per response
(in hrs)
28/60
8/60
20/60
20/60

Total burden
hours
3,319
11,188
3,434
69

39948

Federal Register / Vol. 75, No. 133 / Tuesday, July 13, 2010 / Notices
ESTIMATED ANNUALIZED BURDEN TABLE—Continued
Form

Total ..........................................................................................................

Dated: July 7, 2010.
Carol Walker,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2010–17050 Filed 7–12–10; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0307]

Agency Information Collection
Activities; Proposed Collection;
Comment Request; ‘‘Antiparasitic Drug
Survey’’
AGENCY:

Food and Drug Administration,

HHS.
ACTION:

Notice.

SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
FDA’s ‘‘Antiparasitic Drug Survey.’’
DATES: Submit either electronic or
written comments on the collection of
information by September 13, 2010.
ADDRESSES: Submit electronic
comments on the collection of
information to http://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug

Number of
respondents

Number of
responses per
respondent

Avg. burden
per response
(in hrs)

........................

........................

........................

Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the

Total burden
hours
18,010

information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
‘‘Antiparasitic Drug Survey’’ (OMB
Control Number 0910–NEW)
Resistance of parasites to one or more
of the major classes of FDA approved
antiparasitic drugs is a documented
problem in cattle, horses, sheep, and
goats in the United States. Further, FDA
is aware that there are differing
scientific opinions on the impact of the
use of multiple antiparasitic drugs at the
same time on the development of
resistance to these drugs. The results
from this survey will assist FDA in
regulating antiparasitic drugs. FDA will
also share their results with the
veterinary parasitology community.
FDA plans to survey scientists and
veterinarians with expertise in
veterinary parasitology using a webbased tool. The questions in the survey
are designed to elicit expert opinions
and clarify areas of agreement and
disagreement within the veterinary
parasitology community. The survey
will query subjects on topics such as: (1)
Concurrent use of multiple antiparasitic
drug products, (2) recommended tests to
detect and monitor for antiparasitic
resistance, (3) characteristics of
combination antiparasitic drug products
that may either slow or enhance the
selection for multi-drug resistant
parasites, and (4) regulatory
considerations regarding combination
antiparasitic drugs.
FDA estimates the burden of this
collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
Portion of Study

No. of
respondents

jlentini on DSKJ8SOYB1PROD with NOTICES

Pre-test
Survey

Annual Frequency
per response

Total Annual
Responses

Hours per
Response

5

1

5

.33

1.65

100

1

100

.33

.33

Total
1 There

Total Hours

34.65
are no capital costs or operating and maintenance costs associated with this collection of information.

VerDate Mar<15>2010

16:44 Jul 12, 2010

Jkt 220001

PO 00000

Frm 00039

Fmt 4703

Sfmt 4703

E:\FR\FM\13JYN1.SGM

13JYN1